Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399048 | 0.94 | ALDH1A1 (0.52) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL5401075 | 0.93 | RAB9A (0.48) | EPHX2NR1H4RAB9ANPC1MEN1 | |
| SCHEMBL5402883 | 0.93 | NR1H4 (0.55) | EPHX2NR1H4RAB9ANPC1ALDH1A1 | |
| SCHEMBL5402499 | 0.93 | ALDH1A1 (0.54) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL5398082 | 0.93 | ALDH1A1 (0.54) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL5402275 | 0.92 | HDAC1 (0.55) | EPHX2NR1H4RAB9ANPC1MEN1 | |
| SCHEMBL5403427 | 0.91 | RAB9A (0.56) | EPHX2NR1H4RAB9ANPC1MEN1 | |
| SCHEMBL5397527 | 0.91 | NR1H4 (0.54) | EPHX2NR1H4RAB9ANPC1MEN1 | |
| SCHEMBL5416741 | 0.90 | TP53 (0.49) | RAB9ANPC1ALDH1A1HDAC1HDAC6 | |
| SCHEMBL5401660 | 0.90 | TP53 (0.49) | RAB9ANPC1ALDH1A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | EPHX2 2105/4885NR1H4 546/4885RAB9A 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.